PMID- 29939048
OWN - NLM
STAT- MEDLINE
DCOM- 20181231
LR  - 20190802
IS  - 1936-2293 (Electronic)
IS  - 1064-1297 (Print)
IS  - 1064-1297 (Linking)
VI  - 26
IP  - 4
DP  - 2018 Aug
TI  - Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) and R(-) MDMA on 
      actigraphy-based daytime activity and sleep parameters in rhesus monkeys.
PG  - 410-420
LID - 10.1037/pha0000196 [doi]
AB  - 3,4-Methylenedioxymethamphetamine (MDMA) affects monoaminergic pathways that play 
      a critical role in sleep-wake cycles. Dopaminergic mechanisms are thought to 
      mediate the sleep-disrupting effects of stimulant drugs. However, the mechanisms 
      underlying the effects of MDMA on sleep-wake cycles and the effects of R(-) MDMA, 
      a stereoisomer that lacks dopaminergic activity, on sleep remain unknown. The aim 
      of the present study was to investigate the effects of racemic MDMA and R(-) MDMA 
      on daytime activity and sleep-like parameters evaluated with actigraphy in adult 
      rhesus macaques (Macaca mulatta, n = 6). Actiwatch monitors were attached to the 
      monkeys' collars and actigraphy recording was conducted during baseline 
      conditions and after the administration of acute intramuscular injections of 
      saline (vehicle), racemic MDMA (0.3, 1.0, or 1.7 mg/kg), or R(-) MDMA (0.3, 1.0, 
      or 1.7 mg/kg) at 9 or 16 h (3 h before "lights off"). Morning treatments had no 
      effects on sleep-like parameters. Racemic MDMA decreased general daytime activity 
      during the first hour after injection and increased daytime activity at 3 hr 
      posttreatment. Although afternoon administration of racemic MDMA increased sleep 
      latency, it improved other sleep parameters, decreasing wake time after sleep 
      onset (WASO) and increasing sleep efficiency for subjects with low baseline sleep 
      efficiency. Afternoon treatment with R(-) MDMA improved sleep measures, 
      increasing sleep efficiency and decreasing sleep latency and WASO, while having 
      no effects on daytime activity. The stimulant and sleep-disrupting effects of 
      racemic MDMA are likely mediated by dopaminergic and noradrenergic mechanisms, 
      while serotonergic pathways appear to be involved in the sleep-promoting effects 
      of MDMA. (PsycINFO Database Record
CI  - (c) 2018 APA, all rights reserved).
FAU - Berro, Lais F
AU  - Berro LF
AD  - Yerkes National Primate Research Center.
FAU - Shields, Hannah
AU  - Shields H
AD  - Yerkes National Primate Research Center.
FAU - Odabas-Geldiay, Melis
AU  - Odabas-Geldiay M
AD  - Yerkes National Primate Research Center.
FAU - Rothbaum, Barbara O
AU  - Rothbaum BO
AD  - Department of Psychiatry and Behavioral Science.
FAU - Andersen, Monica L
AU  - Andersen ML
AD  - Yerkes National Primate Research Center.
FAU - Howell, Leonard L
AU  - Howell LL
AD  - Department of Psychiatry and Behavioral Science.
LA  - eng
GR  - P51 OD011132/OD/NIH HHS/United States
GR  - Fundacao de Amparo a Pesquisa do Estado de Sao Paulo/International
GR  - R37 DA010344/DA/NIDA NIH HHS/United States
GR  - R01 DA010344/DA/NIDA NIH HHS/United States
GR  - AFIP/International
GR  - K05 DA031246/DA/NIDA NIH HHS/United States
GR  - US PHS/International
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180625
PL  - United States
TA  - Exp Clin Psychopharmacol
JT  - Experimental and clinical psychopharmacology
JID - 9419066
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Hallucinogens)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Actigraphy/*methods
MH  - Animals
MH  - Central Nervous System Stimulants/pharmacology
MH  - Female
MH  - Hallucinogens/chemistry
MH  - Macaca mulatta
MH  - Male
MH  - Motor Activity/*drug effects/physiology
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage/*chemistry
MH  - Sleep/*drug effects/physiology
MH  - Wakefulness/*drug effects/physiology
PMC - PMC6072597
MID - NIHMS944875
EDAT- 2018/06/26 06:00
MHDA- 2019/01/01 06:00
PMCR- 2019/08/01
CRDT- 2018/06/26 06:00
PHST- 2018/06/26 06:00 [pubmed]
PHST- 2019/01/01 06:00 [medline]
PHST- 2018/06/26 06:00 [entrez]
PHST- 2019/08/01 00:00 [pmc-release]
AID - 2018-29492-001 [pii]
AID - 10.1037/pha0000196 [doi]
PST - ppublish
SO  - Exp Clin Psychopharmacol. 2018 Aug;26(4):410-420. doi: 10.1037/pha0000196. Epub 
      2018 Jun 25.